CYP2D6、CYP2C9、CYP2C19和CYP3A5药物基因组表型与退伍军人多重用药的关联
本研究为回顾性队列研究,纳入13,116例接受VA药物基因组检测且符合标准的退伍军人患者,评估CYP2D6、CYP2C9、CYP2C19和CYP3A5的可干预表型与多重用药的关联。结果显示,全体药物多重用药与表型总数无显著关联,但在处方≥1种受PGx影响药物的患者中,表型越多者达到多重用药标准的比例越高(51%、52%、58%,P=0.03,OR 1.31,95%CI 1.02-1.67)。
要点
- 表型总数与全体药物多重用药无显著关联
- 在处方≥1种PGx影响药物者中,表型越多多重用药比例越高
- 受PGx影响药物数的中位数随表型组增加而升高
核心结论
- 在处方≥1种受PGx影响药物的患者中,可干预药物基因组表型越多者越可能符合多重用药标准。
- 全体药物多重用药、总药物数及受表型影响药物数与表型总数无显著关联。
研究设计与样本
- 回顾性队列研究,纳入接受VA药物基因组检测且有VA处方的退伍军人患者。
- 共筛查15,144例,13,116例符合纳入标准。
- 多重用药定义为≥10种药物,构建两个共同主要终点:基于所有药物和需至少1种药物受目标药物基因组影响。
主要发现
- 表型组间全体药物多重用药、总药物数及受表型影响药物数无显著差异。
- 在处方≥1种受PGx影响药物的患者中,多重用药比例分别为2,514/4,949(51%)、1,349/2,595(52%)、204/350(58%)(P=0.03,OR 1.31,95%CI 1.02-1.67)。
- 受PGx表型影响药物数的中位数在表型组间分别为0(IQR 0,0)、0(IQR 0,0)和1(IQR 0,1)(P<0.001)。
关键数值与推荐
- 目标药物基因组及可干预表型:CYP2D6、CYP2C9、CYP2C19的慢代谢型和超快代谢型,CYP3A5的中间代谢型和正常代谢型。
- 患者按所有基因的可干预表型总数分为0、1和2+组。
临床怎么用
- 对已处方受PGx影响药物的患者,可关注可干预表型数量以识别多重用药高风险者。
- 药物基因组表型可能有助于优化多重用药管理,但需结合用药清单综合评估。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Department of Veterans Affairs (VA) utilizes a pharmacogenomic (PGx) program that analyzes specific "pharmacogenes." This study evaluates the effect that pharmacogenes may have on prevalence of polypharmacy. This retrospective cohort study included patients with VA prescriptions who underwent PGx testing. We quantified prescriptions active or recently expired at the time of PGx testing. We constructed two co-primary polypharmacy (≥10 medications) end points: (i) based on all medications and (ii) requiring that at least one medication was affected by a pharmacogene of interest. Pharmacogenes and actionable phenotypes of interest included poor and ultrarapid metabolizers for CYP2D6, CYP2C9, and CYP2C19 and intermediate and normal metabolizers for CYP3A5. Patients were classified as having 0, 1, and 2+ total phenotypes across all genes. Of the 15,144 patients screened, 13,116 met eligibility criteria. Across phenotype cohorts, there was no significant association with polypharmacy using all medications, number of total medications, or number of medications affected by phenotypes. However, there was a significant difference in patients with polypharmacy prescribed ≥1 medication impacted by PGx across phenotype groups: 2,514/4,949 (51%), 1,349/2,595 (52%), 204/350 (58%) (P = 0.03, OR 1.31, 95% CI 1.02-1.67). The median number of medications affected by PGx phenotypes with ≥1 PGx-impacted medication across phenotype groups was a median of 0 (IQR 0, 0), 0 (IQR 0, 0), and 1 (IQR 0, 1) (P < 0.001). In patients prescribed ≥1 medication impacted by PGx, those with more actionable pharmacogenomic phenotypes were more likely to meet polypharmacy criteria.
引用
- Krulikas L, Bates J, Chanfreau C, et al. Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans. Clin Pharmacol Ther. 2024. PMID: 38775021. doi:10.1002/cpt.3297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。